Background The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients
with good or low surgical risk is primarily surgical resection. However, this area is …

BACKGROUND: Decisions about chemotherapy for NSCLC are complex and involve trade-
offs between its benefits, harms and inconveniences. We sought to find, evaluate and …

Background Adjuvant chemotherapy (AC) is recommended since 2004 for patients with a
completely resected non-small cell lung cancer (NSCLC). Indeed, several randomized …

The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document:
Staging and multidisciplinary management of patients with early-stage non–small cell lung …

Purpose Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
proven efficacy in advanced non–small-cell lung cancer (NSCLC). Their role in early-stage …

Purpose Non–small-cell lung cancer (NSCLC) is predominantly a disease of the elderly.
Retrospective analyses of the National Cancer Institute of Canada Clinical Trials Group JBR …

Purpose Since 2004, several clinical trials have demonstrated that adjuvant chemotherapy
(ACT) improves survival in patients with early-stage non–small-cell lung cancer (NSCLC) …

Background Practice guidelines from the National Comprehensive Cancer Network and the
American Society of Clinical Oncology recommend pathologic mediastinal staging and …

BACKGROUND Despite clinical trials demonstrating improved survival with adjuvant
chemotherapy (AC) for patients with American Joint Committee on Cancer stages I to III non …

Background Surgical resection with lobectomy is recommended for T1/T2 N0 small cell lung
cancer (SCLC) patients after negative mediastinal staging. We sought to characterize …